<DrugInformationSummary id="CDR0000816806"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Kisqali Femara Co-Pack combines two drugs into one package: ribociclib succinate (Kisqali) and letrozole (Femara). Ribociclib succinate is a targeted therapy drug that blocks proteins called CDK4 and CDK6 that cancer cells need to grow. Letrozole is a hormone therapy and targeted therapy drug that blocks a protein called aromatase, which the body uses to make estrogen. Blocking aromatase lowers estrogen levels, which helps slow or stop the growth of breast cancer cells that need estrogen to grow.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/ribociclib-succinate-and-letrozole">Ribociclib Succinate and Letrozole</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000816801">ribociclib succinate/letrozole</TerminologyLink><GlossaryLink ref="CDR0000816813">ribociclib succinate and letrozole</GlossaryLink><USBrandNames><USBrandName>Kisqali Femara Co-Pack</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>RY-boh-SY-klib SUK-sih-nayt â€¦ LEH-truh-zole</TermPronunciation><MediaLink ref="CDR0000817423" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000817424" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa5e4446-19cd-4235-a382-5b48bf6c3b2f&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Ribociclib Succinate and Letrozole</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa5e4446-19cd-4235-a382-5b48bf6c3b2f&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">The <GlossaryTermRef href="CDR0000787678" dictionary="Cancer.gov" audience="Patient">ribociclib succinate</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045421" dictionary="Cancer.gov" audience="Patient">letrozole</GlossaryTermRef> co-pack
         is approved to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000444971" dictionary="Cancer.gov" audience="Patient">breast cancer</GlossaryTermRef></Strong> that is <GlossaryTermRef href="CDR0000788029" dictionary="Cancer.gov" audience="Patient">hormone receptor positive</GlossaryTermRef> (HR+) and <GlossaryTermRef href="CDR0000774531" dictionary="Cancer.gov" audience="Patient">HER2 negative</GlossaryTermRef> (HER2-). It is used:<ItemizedList Style="bullet" id="_5"><ListItem>for stage II or stage III <GlossaryTermRef href="CDR0000446564" dictionary="Cancer.gov" audience="Patient">early breast cancer</GlossaryTermRef> that is at high risk of coming back</ListItem><ListItem>as the first <GlossaryTermRef href="CDR0000045110" dictionary="Cancer.gov" audience="Patient">hormone-based therapy</GlossaryTermRef> for  cancer that has spread</ListItem></ItemizedList></ListItem>
   </ItemizedList>
  <Para id="_4">Ribociclib succinate and letrozole
         are also available separately as ribociclib succinate  and letrozole. For more information that may apply to these drugs, see the Drug Information Summaries for <DrugRef href="CDR0000787676" url="/about-cancer/treatment/drugs/ribociclib">Ribociclib Succinate</DrugRef> and <DrugRef href="CDR0000495423" url="/about-cancer/treatment/drugs/letrozole">Letrozole</DrugRef>.</Para>
 </Section><Section id="_About"><Title>More About Ribociclib Succinate and Letrozole</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/816801">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2021/ribociclib-improves-metastatic-breast-cancer-survival">Combo of Ribociclib, Letrozole Improves Survival in Advanced Breast Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet">Hormone Therapy to Treat Breast Cancer</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C154675">Find Clinical Trials for Ribociclib Succinate/letrozole</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2024-10-25</DateFirstPublished></DrugInformationSummary>
